Schrödinger Past Earnings Performance
Past criteria checks 0/6
Schrödinger's earnings have been declining at an average annual rate of -7.1%, while the Healthcare Services industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 22.3% per year.
Key information
-7.1%
Earnings growth rate
31.4%
EPS growth rate
Healthcare Services Industry Growth | 1.7% |
Revenue growth rate | 22.3% |
Return on equity | -27.9% |
Net Margin | -75.9% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar
May 02Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially
Mar 01Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
Mar 01Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Feb 28The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%
Feb 01Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable
Dec 18Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Sep 28Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?
Jul 01Schrödinger: Q2 Earnings Supports Growth Narrative
Aug 26Schrödinger appoints Dr. Geoffrey Porges as finance chief
Aug 18Sizing Up Schrodinger
Jun 06Schrödinger: Holding The Keys To Discovery
Mar 26Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too
Mar 15Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical
Jan 06After Its Stock Price Doubled Last Year, Why Schrödinger Is Slumping Now
Nov 24We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow
Nov 12An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 38% Undervalued
Oct 05Schrodinger: An Investment In Drug Discovery In Addition To Software Sales
Sep 20Schrodinger: Competitive Advantages Galore
Jul 07Estimating The Intrinsic Value Of Schrödinger, Inc. (NASDAQ:SDGR)
Jun 28Revenue & Expenses BreakdownBeta
How Schrödinger makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 188 | -143 | 137 | 192 |
31 Dec 23 | 217 | 41 | 136 | 182 |
30 Sep 23 | 199 | 44 | 133 | 165 |
30 Jun 23 | 194 | 66 | 131 | 151 |
31 Mar 23 | 197 | 14 | 128 | 139 |
31 Dec 22 | 181 | -149 | 121 | 126 |
30 Sep 22 | 170 | -153 | 112 | 117 |
30 Jun 22 | 163 | -148 | 105 | 107 |
31 Mar 22 | 154 | -135 | 96 | 97 |
31 Dec 21 | 138 | -100 | 86 | 91 |
30 Sep 21 | 125 | -81 | 81 | 83 |
30 Jun 21 | 121 | -42 | 72 | 77 |
31 Mar 21 | 114 | -11 | 65 | 72 |
31 Dec 20 | 108 | -24 | 60 | 65 |
30 Sep 20 | 101 | -20 | 54 | 58 |
30 Jun 20 | 95 | -35 | 52 | 52 |
31 Mar 20 | 91 | -33 | 52 | 45 |
31 Dec 19 | 86 | -25 | 48 | 39 |
30 Sep 19 | 77 | -24 | 46 | 37 |
30 Jun 19 | 70 | -24 | 43 | 36 |
31 Mar 19 | 69 | -29 | 38 | 35 |
31 Dec 18 | 67 | -28 | 36 | 35 |
31 Dec 17 | 56 | -17 | 31 | 28 |
Quality Earnings: SDGR is currently unprofitable.
Growing Profit Margin: SDGR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SDGR is unprofitable, and losses have increased over the past 5 years at a rate of 7.1% per year.
Accelerating Growth: Unable to compare SDGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SDGR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).
Return on Equity
High ROE: SDGR has a negative Return on Equity (-27.86%), as it is currently unprofitable.